Your browser doesn't support javascript.
loading
Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.
Nassar, Amin H; Abou Alaiwi, Sarah; Baca, Sylvan C; Adib, Elio; Corona, Rosario I; Seo, Ji-Heui; Fonseca, Marcos A S; Spisak, Sandor; El Zarif, Talal; Tisza, Viktoria; Braun, David A; Du, Heng; He, Monica; Flaifel, Abdallah; Alchoueiry, Michel; Denize, Thomas; Matar, Sayed G; Acosta, Andres; Shukla, Sachet; Hou, Yue; Steinharter, John; Bouchard, Gabrielle; Berchuck, Jacob E; O'Connor, Edward; Bell, Connor; Nuzzo, Pier Vitale; Mary Lee, Gwo-Shu; Signoretti, Sabina; Hirsch, Michelle S; Pomerantz, Mark; Henske, Elizabeth; Gusev, Alexander; Lawrenson, Kate; Choueiri, Toni K; Kwiatkowski, David J; Freedman, Matthew L.
Afiliación
  • Nassar AH; Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, 06510, USA.
  • Abou Alaiwi S; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Adib E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Corona RI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Seo JH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Fonseca MAS; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Spisak S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • El Zarif T; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Tisza V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Braun DA; Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Du H; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • He M; Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Flaifel A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Alchoueiry M; Women's Cancer Research Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Denize T; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Matar SG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Acosta A; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Shukla S; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA.
  • Hou Y; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Steinharter J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Bouchard G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Berchuck JE; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • O'Connor E; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA.
  • Bell C; Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, CT, 06510, USA.
  • Nuzzo PV; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Mary Lee GS; The Eli and Edythe L. Broad Institute, Cambridge, MA, 02142, USA.
  • Signoretti S; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Hirsch MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Pomerantz M; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Henske E; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Gusev A; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Lawrenson K; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Choueiri TK; Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
  • Kwiatkowski DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Freedman ML; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Commun ; 14(1): 346, 2023 01 21.
Article en En | MEDLINE | ID: mdl-36681680
ABSTRACT
While the mutational and transcriptional landscapes of renal cell carcinoma (RCC) are well-known, the epigenome is poorly understood. We characterize the epigenome of clear cell (ccRCC), papillary (pRCC), and chromophobe RCC (chRCC) by using ChIP-seq, ATAC-Seq, RNA-seq, and SNP arrays. We integrate 153 individual data sets from 42 patients and nominate 50 histology-specific master transcription factors (MTF) to define RCC histologic subtypes, including EPAS1 and ETS-1 in ccRCC, HNF1B in pRCC, and FOXI1 in chRCC. We confirm histology-specific MTFs via immunohistochemistry including a ccRCC-specific TF, BHLHE41. FOXI1 overexpression with knock-down of EPAS1 in the 786-O ccRCC cell line induces transcriptional upregulation of chRCC-specific genes, TFCP2L1, ATP6V0D2, KIT, and INSRR, implicating FOXI1 as a MTF for chRCC. Integrating RCC GWAS risk SNPs with H3K27ac ChIP-seq and ATAC-seq data reveals that risk-variants are significantly enriched in allelically-imbalanced peaks. This epigenomic atlas in primary human samples provides a resource for future investigation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos